Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Amortization - Intangibles: 2009-2024

Historic Amortization - Intangibles for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to $7.3 million.

  • Vanda Pharmaceuticals' Amortization - Intangibles changed negligibly% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year increase of 8.84%. This contributed to the annual value of $7.3 million for FY2024, which is 247.99% up from last year.
  • As of FY2024, Vanda Pharmaceuticals' Amortization - Intangibles stood at $7.3 million, which was up 247.99% from $2.1 million recorded in FY2023.
  • Vanda Pharmaceuticals' Amortization - Intangibles' 5-year high stood at $7.3 million during FY2024, with a 5-year trough of $1.5 million in FY2020.
  • Its 3-year average for Amortization - Intangibles is $3.6 million, with a median of $2.1 million in 2023.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Amortization - Intangibles declined by 1.79% in 2020 and then soared by 247.99% in 2024.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Amortization - Intangibles stood at $1.5 million in 2020, then remained steady at $1.5 million in 2021, then grew by 2.57% to $1.5 million in 2022, then spiked by 37.86% to $2.1 million in 2023, then spiked by 247.99% to $7.3 million in 2024.